Browse Category

Pharmaceuticals 28 July 2026 - 5 August 2026

Amgen (NASDAQ:AMGN) raises 2026 guidance as five key brands counter $772 million decline

Amgen Inc. increased its 2026 revenue midpoint forecast by $1 billion. Five key brands delivered a combined $923 million in year-over-year quarterly sales gains, accounting for 120% of the company’s $766 million rise in product sales.

5 August 2026

Earnings·NASDAQ:AMGN·Pharmaceuticals·Stock Market

Novo Nordisk (CPH:NOVO-B; NYSE:NVO) ADR drops after Q2 results outpace forecasts, paving way for possible rebound in Copenhagen

Novo Nordisk’s U.S. ADR dropped 6.8% on Tuesday even after the company reported earnings that surpassed expectations. The decline indicates lingering investor doubts about the strength of its recovery.

4 August 2026

Earnings·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Pfizer Tops Q2 Estimates as Main Drug Revenue Balances Drop in COVID Sales

Pfizer Inc. increased its 2026 minimum sales outlook following stronger-than-expected quarterly results. Key insight for investors lies within the updated guidance breakdown. Non-COVID product sales rose by $1.5 billion, offset by a $1 billion decline in COVID-related sales.

4 August 2026

Earnings·NYSE:PFE·Pharmaceuticals·Stock Market

Vertex Pharmaceuticals lifts forecast as non-CF portfolio heads into 53% second-half hurdle

Vertex Pharmaceuticals Incorporated lifted its yearly sales forecast as cystic-fibrosis treatments fueled a 12% rise in quarterly revenue. Shares traded almost flat around $470 following hours, after a 1.3% drop to $470.72 at the close.

4 August 2026

Biotechnology·Earnings·NASDAQ:VRTX·Pharmaceuticals·Stock Market

TG Therapeutics (NASDAQ:TGTX) falls as BRIUMVI revenue increase outweighed by rising costs

TG Therapeutics Inc shares fell in early trading in New York on Monday, as stronger BRIUMVI sales did not offset a significant earnings shortfall and broader spending outlook. Evercore ISI analyst Michael DiFiore noted that analysts were “underestimating operating expenses.”

3 August 2026

Earnings·NASDAQ:TGTX·Pharmaceuticals·Stock Market

Bristol Myers rises on AstraZeneca merger speculation, but market-cap figures urge restraint

Bristol-Myers Squibb Company gained approximately 8% in premarket trade ahead of the start of regular U.S. trading, following news of initial discussions with AstraZeneca PLC.

3 August 2026

LON:AZN·NYSE:BMY·Pharmaceuticals·Stock Market

AstraZeneca (LON:AZN) falls as news of deal talks wipes out about $5 billion in total value

AstraZeneca shares dropped roughly 5% on Monday following news of early-stage merger discussions. Bristol Myers gained approximately 6% ahead of the New York cash session.

3 August 2026

LON:AZN·Pharmaceuticals·Stock Market

Universe Pharmaceuticals (NASDAQ:UPC) surges 134% as acquisition boosts shares outstanding nearly eightfold

Shares of Universe Pharmaceuticals INC surged over 100% ahead of Monday's session after the company revealed the completion of its Best Praise International acquisition. With the primary Nasdaq market still closed, trading was occurring in the premarket.

3 August 2026

NASDAQ:UPC·Pharmaceuticals·Stock Market

FDA Decision on Replimune (NASDAQ:REPL) Prompts $763 Million in Melanoma Stock Shifts

A positive FDA decision triggered the movement of nearly $763 million between two melanoma stocks on Friday. Replimune Group saw an increase of around $486 million, while Iovance Biotherapeutics lost approximately $277 million. These figures are based on the most recent common-share counts reported by the companies.

3 August 2026

Biotechnology·NASDAQ:IOVA·NASDAQ:REPL·Pharmaceuticals·Stock Market

Bristol Myers Squibb (NYSE:BMY) faces valuation test Monday as report of potential partnership emerges

Bristol Myers Squibb Company started Monday following reports of a potential major deal. According to the Financial Times, AstraZeneca PLC considered a merger valued at close to $400 billion. AstraZeneca declined to comment. Bristol Myers did not immediately provide a response, and Reuters was unable to independently confirm the story. U.S. financial markets were closed Sunday.

2 August 2026

NYSE:AZN·NYSE:BMY·Pharmaceuticals·Stock Market

AstraZeneca (NYSE:AZN)–Bristol Myers Squibb (NYSE:BMY): Potential $455 Billion Tie-Up Raises Questions Over Deal Value

A potential deal under discussion could create one of the biggest mergers in the pharmaceutical sector. The Financial Times reported that talks have occurred over the past few months. As of Friday, the combined market value was $396.4 billion. Reuters has not confirmed the report, and there is no guarantee that a deal will be reached.

2 August 2026

NYSE:AZN·NYSE:BMY·Pharmaceuticals·Stock Market

Apnimed (NASDAQ:APMD) soars 56% as FDA decision could push sleep-apnea valuation close to $1 billion

Apnimed Inc. finished its first session on Nasdaq at $25, representing a 56.25% increase from its IPO price of $16. Market data indicated a market capitalization close to $950 million. The regular session had ended, but after-hours trading was still ongoing. The stock was last quoted at $23, reflecting an 8% drop from the closing price.

1 August 2026

NASDAQ:APMD·Pharmaceuticals·Stock Market

Replimune (NASDAQ:REPL) Shares Soar as FDA Panel Supports RP1 Despite Ongoing Evidence Debate

Replimune stock finished Friday at $11.20, gaining 107.0%. The surge came after an FDA advisory panel voted 10–3 in favor of RP1. The company's reported market capitalization jumped by about $485 million to $940.2 million. Trading volume was 33.38 million shares, 7.5 times the usual level.

31 July 2026

Biotechnology·NASDAQ:REPL·Pharmaceuticals·Stock Market

Pfizer (NYSE:PFE) Stock Gains Before Q2 as Eliquis Read-Through Strengthens

Pfizer Inc. enters Tuesday’s results with a stronger Eliquis signal. Its partner posted a 22% sales jump before Pfizer’s own report.

31 July 2026

Earnings·NYSE:PFE·Pharmaceuticals·Stock Market

Mangoceuticals (NASDAQ:MGRX) Shares Surge Almost Threefold Following Nuclea Agreement; Existing Shareholders Retain 4%

Mangoceuticals shares surged almost threefold on Friday morning following the announcement of a nuclear reverse merger. The stock traded at $0.8029, marking a 173.5% increase from the previous day's close, after touching a high of $1.23 earlier. Trading volume surpassed 350.5 million shares.

31 July 2026

NASDAQ:MGRX·Pharmaceuticals·Stock Market

Novo Nordisk shares fall after ZEUS trial disappointment highlights 94% sales reliance

Shares of Novo Nordisk A/S dropped significantly on Friday after the ZEUS trial found minimal cardiovascular benefit from ziltivekimab. The decline in U.S. trading wiped out approximately $20.5 billion in market capitalisation.

31 July 2026

CPH:NOVO-B·Earnings·NYSE:NVO·Pharmaceuticals·Stock Market

Corcept Therapeutics (NASDAQ:CORT) surges 27% after Lifyorli boosts second-half expectations

Shares of Corcept Therapeutics Incorporated jumped 27.4% to $118.41 as of 13:45 EDT. The company reported a 32% increase in quarterly sales and lifted its full-year guidance.

30 July 2026

Earnings·NASDAQ:CORT·NASDAQ:XERS·Pharmaceuticals·Stock Market

Alnylam Pharmaceuticals (NASDAQ:ALNY) drops 28% as company lowers Amvuttra outlook

Alnylam stock dropped 28.4% to $205.25 during active trading on the Nasdaq on Thursday. The company revised its 2026 transthyretin product revenue forecast lower by $200 million at the midpoint.

30 July 2026

Earnings·Pharmaceuticals·Stock Market

AtaiBeckley Shares at $7.17 as Lilly Agreement Sets CVR at 42 Cents

Shares of AtaiBeckley Inc. remained flat at $7.17 as of 1 p.m. on Tuesday. This price stood 42 cents higher than Eli Lilly and Co.'s $6.75 cash offer at close.

28 July 2026

NASDAQ:ATAI·NYSE:LLY·Pharmaceuticals·Stock Market

Altimmune (NASDAQ:ALT) shares rise following alcohol-use disorder trial, with attention turning to $225 million in warrants

Altimmune stock gained roughly 10% in premarket trading on Tuesday. The company’s Phase 2 RECLAIM study showed pemvidutide achieved its primary endpoint. U.S. markets had not opened at the time of reporting.

28 July 2026

NASDAQ:ALT·Pharmaceuticals·Stock Market

Previous 1 2 3 4 … 47 Next

Pharmaceuticals 28 July 2026 - 5 August 2026

Amgen (NASDAQ:AMGN) raises 2026 guidance as five key brands counter $772 million decline

Novo Nordisk (CPH:NOVO-B; NYSE:NVO) ADR drops after Q2 results outpace forecasts, paving way for possible rebound in Copenhagen

Pfizer Tops Q2 Estimates as Main Drug Revenue Balances Drop in COVID Sales

Vertex Pharmaceuticals lifts forecast as non-CF portfolio heads into 53% second-half hurdle

TG Therapeutics (NASDAQ:TGTX) falls as BRIUMVI revenue increase outweighed by rising costs

Bristol Myers rises on AstraZeneca merger speculation, but market-cap figures urge restraint

AstraZeneca (LON:AZN) falls as news of deal talks wipes out about $5 billion in total value

Universe Pharmaceuticals (NASDAQ:UPC) surges 134% as acquisition boosts shares outstanding nearly eightfold

FDA Decision on Replimune (NASDAQ:REPL) Prompts $763 Million in Melanoma Stock Shifts

Bristol Myers Squibb (NYSE:BMY) faces valuation test Monday as report of potential partnership emerges

AstraZeneca (NYSE:AZN)–Bristol Myers Squibb (NYSE:BMY): Potential $455 Billion Tie-Up Raises Questions Over Deal Value

Apnimed (NASDAQ:APMD) soars 56% as FDA decision could push sleep-apnea valuation close to $1 billion

Replimune (NASDAQ:REPL) Shares Soar as FDA Panel Supports RP1 Despite Ongoing Evidence Debate

Pfizer (NYSE:PFE) Stock Gains Before Q2 as Eliquis Read-Through Strengthens

Mangoceuticals (NASDAQ:MGRX) Shares Surge Almost Threefold Following Nuclea Agreement; Existing Shareholders Retain 4%

Novo Nordisk shares fall after ZEUS trial disappointment highlights 94% sales reliance

Corcept Therapeutics (NASDAQ:CORT) surges 27% after Lifyorli boosts second-half expectations

Alnylam Pharmaceuticals (NASDAQ:ALNY) drops 28% as company lowers Amvuttra outlook

AtaiBeckley Shares at $7.17 as Lilly Agreement Sets CVR at 42 Cents

Altimmune (NASDAQ:ALT) shares rise following alcohol-use disorder trial, with attention turning to $225 million in warrants

TechStock² Updates

Riot Platforms (RIOT) Rises as $9.1 Billion AI Deal Sets Higher Benchmark for Delivery

CAVA Shares Climb 12% Despite Margin Dip as Customer Traffic Rises

Cisco shares fall after earnings highlight $3.7 billion AI order surge

Alamar Biosciences Shares (ALMR) Surge 31% as Consumables Drive Gross Margin Up

JetBlue Shares Bounce 3% After Four-Session Losing Streak; Volume Remains Light

Top Stock Picks

Taiwan Semiconductor

AerCap

Constellation Energy

Walt Disney

American International Group

Live updates

Investment Disclaimer